Dec 19, 2019 1:14 pm EST Capricor Therapeutics Announces Closing of $5.1 Million Offering Priced At-the-Market
Dec 17, 2019 1:52 pm EST Capricor Therapeutics Announces Pricing of $5.1 Million Offering Priced At-the-Market
Nov 07, 2019 4:00 pm EST Capricor Therapeutics Reports Third Quarter 2019 Financial Results and Provides Recent Corporate Update
Nov 01, 2019 9:00 am EDT Capricor Therapeutics to Present Third Quarter 2019 Financial Results and Recent Corporate Update on November 7
Oct 21, 2019 9:25 am EDT Capricor Therapeutics to Host Key Opinion Leader Call on the Role of CAP-1002 for the Treatment of Duchenne Muscular Dystrophy (DMD)
Oct 07, 2019 6:30 am EDT Capricor Presents Additional Positive Data from Ongoing HOPE-2 Study of CAP-1002 in Duchenne Muscular Dystrophy at World Muscle Society: Data Demonstrates Improved PUL 2.0 Performance at 6 Months
Oct 02, 2019 9:15 am EDT Capricor to Present Interim Results from the HOPE-2 Trial in a Late Breaking Session of the World Muscle Society and Company to Host Conference Call Monday, October 7 at 5:30 AM PT / 8:30 AM ET
Sep 24, 2019 7:30 am EDT Capricor Therapeutics to Meet with FDA to Discuss CAP-1002 to Treat Duchenne Muscular Dystrophy
Sep 17, 2019 7:00 am EDT Capricor Therapeutics to Present Results from the HOPE-2 Trial of CAP-1002 in Duchenne Muscular Dystrophy in a Late Breaking Session of the World Muscle Society